111 related articles for article (PubMed ID: 17998245)
21. Platelet Factor 4 as a Novel Exosome Marker in MALDI-MS Analysis of Exosomes from Human Serum.
Nguyen HQ; Lee D; Kim Y; Paek M; Kim M; Jang KS; Oh J; Lee YS; Yeon JE; Lubman DM; Kim J
Anal Chem; 2019 Oct; 91(20):13297-13305. PubMed ID: 31549806
[TBL] [Abstract][Full Text] [Related]
22. Low Platelet Counts at Diagnosis Predict Better Survival for Patients with Intermediate-Risk Acute Myeloid Leukemia.
Zhang Y; Gu H; Chen Q; Zhang Y; Cheng H; Yang J; Wang J; Hu X
Acta Haematol; 2020; 143(1):9-18. PubMed ID: 31167182
[TBL] [Abstract][Full Text] [Related]
23. Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens.
Bai J; Wang J; Yang Y; Zhang W; Wang F; Zhang L; Chen H; Wang X; Feng Y; Shen Y; Huang L; He A
Hematology; 2019 Dec; 24(1):387-391. PubMed ID: 30890040
[TBL] [Abstract][Full Text] [Related]
24. Absolute immature platelet counts in the setting of suspected heparin-induced thrombocytopenia may predict anti-PF4-heparin immunoassay testing results.
Chen W; Ha JP; Hong H; Maitta RW
Transfus Apher Sci; 2018 Aug; 57(4):507-511. PubMed ID: 29661682
[TBL] [Abstract][Full Text] [Related]
25. Elevated serum endostatin levels are associated with favorable outcome in acute myeloid leukemia.
Aref S; El-Sherbiny M; Azmy E; Goda T; Selim T; El-Refaie M; Twafik E
Hematology; 2008 Apr; 13(2):95-100. PubMed ID: 18616876
[TBL] [Abstract][Full Text] [Related]
26. Complete, yet partial: the benefits of complete response with partial haematological recovery as an endpoint in acute myeloid leukaemia clinical trials.
Shallis RM; Pollyea DA; Zeidan AM
Lancet Haematol; 2020 Dec; 7(12):853-856. PubMed ID: 33242436
[No Abstract] [Full Text] [Related]
27. Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone.
Voog E; Le QH; Philip I; Benetaib B; Michallet M; Fiere D; Thomas X
Ann Hematol; 2001 Oct; 80(10):584-91. PubMed ID: 11732869
[TBL] [Abstract][Full Text] [Related]
28. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.
Xu PP; Chen BA; Feng JF; Cheng L; Xia GH; Li YF; Qian J; Ding JH; Lu ZH; Wang XM; Xu K; Schultz M
Chin Med J (Engl); 2012 Jun; 125(12):2137-43. PubMed ID: 22884143
[TBL] [Abstract][Full Text] [Related]
29. Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients.
Su YZ; Wang CB; Zhou Y; Sun NT
Genet Mol Res; 2015 May; 14(2):5181-7. PubMed ID: 26125711
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of blood and marrow findings in acute myelogenous leukemia in remission. A Southeastern Cancer Study Group report.
Vogler WR; Raney MR
Cancer; 1988 Jun; 61(12):2481-6. PubMed ID: 3163256
[TBL] [Abstract][Full Text] [Related]
31. Outcomes in obese patients undergoing induction therapy for acute leukemia.
Dombrowski L; Mohassel L
J Oncol Pharm Pract; 2019 Jul; 25(5):1058-1065. PubMed ID: 29726788
[TBL] [Abstract][Full Text] [Related]
32. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome.
Hsu HC; Lee YM; Tsai WH; Jiang ML; Ho CH; Ho CK; Wang SY
Oncology; 2002; 63(1):64-9. PubMed ID: 12187073
[TBL] [Abstract][Full Text] [Related]
33. Response in acute myeloid leukemia.
Estey E
Clin Adv Hematol Oncol; 2008 Feb; 6(2):113-7. PubMed ID: 18347562
[TBL] [Abstract][Full Text] [Related]
34. Detection of lung adenocarcinoma using magnetic beads based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry serum protein profiling.
Lin XL; Yang SY; Du J; Tian YX; Bu LN; Huo SF; Wang FP; Nan YD
Chin Med J (Engl); 2010 Jan; 123(1):34-9. PubMed ID: 20137572
[TBL] [Abstract][Full Text] [Related]
35. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
[TBL] [Abstract][Full Text] [Related]
36. Platelet-Activating Antibodies Are Detectable at the Earliest Onset of Heparin-Induced Thrombocytopenia, With Implications for the Operating Characteristics of the Serotonin-Release Assay.
Warkentin TE; Arnold DM; Kelton JG; Sheppard JI; Smith JW; Nazy I
Chest; 2018 Jun; 153(6):1396-1404. PubMed ID: 29325985
[TBL] [Abstract][Full Text] [Related]
37. The rise of reticulated platelets after intensive chemotherapy for AML reduces the need for platelet transfusions.
Stohlawetz P; Stiegler G; Knöbl P; Höcker P; Panzer S
Ann Hematol; 1999 Jun; 78(6):271-3. PubMed ID: 10422629
[TBL] [Abstract][Full Text] [Related]
38. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
[TBL] [Abstract][Full Text] [Related]
39. Delayed-onset effect of clofarabine in the treatment of an adult patient with acute myeloid leukemia.
Walchack R; Cumpston A; Vos J; Kanate AS
Am J Health Syst Pharm; 2019 Feb; 76(6):349-352. PubMed ID: 31361841
[TBL] [Abstract][Full Text] [Related]
40. [Establishment of diagnostic model to monitor minimal residual disease of acute promyelocytic leukemia by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry].
Zhang LL; Xu ZF; Tan YH; Chen XH; Xu AN; Ren FG; Wang HW
Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):16-20. PubMed ID: 23597458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
